Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free GMAB Stock Alerts

Genmab A/S (GMAB) Financials

Genmab A/S logo
$27.53 +0.49 (+1.80%)
Closing price 03:59 PM Eastern
Extended Trading
$27.53 +0.00 (+0.01%)
As of 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Genmab A/S

Annual Income Statements for Genmab A/S

This table shows Genmab A/S's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 178 226 0.00 0.00 0.00 770 1,133 963
Consolidated Net Income / (Loss)		 178 226 0.00 0.00 0.00 631 1,133 963
Net Income / (Loss) Continuing Operations		 178 226 325 782 458 631 1,133 963
Total Pre-Tax Income 		172 247 430 970 606 817 1,326 1,204
Total Operating Income		 217 212 396 1,038 459 772 972 1,065
Total Gross Profit		 382 464 806 1,662 1,291 2,357 2,978 3,482
Total Revenue		 382 464 806 1,662 1,291 2,390 3,121 3,720
Operating Revenue		 382 464 - - - 2,390 3,121 3,720
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 33 143 238
Operating Cost of Revenue		 - - - - - 33 143 238
Total Operating Expenses		 165 252 410 624 832 1,585 2,006 2,417
Selling, General & Admin Expense		 24 33 51 109 195 478 549 626
Research & Development Expense		 141 220 359 516 636 1,107 1,414 1,606
Restructuring Charge		 - - - - - - 43 185
Total Other Income / (Expense), net		 -45 36 33 -67 147 45 354 139
Interest Expense		 57 1.69 1.05 256 107 254 291 269
Interest & Investment Income		 12 37 34 189 254 299 645 408
Income Tax Expense		 -6.46 21 104 188 148 186 193 241
Weighted Average Basic Shares Outstanding		 - - 93.01M - - - - 128.62M
Weighted Average Diluted Shares Outstanding		 - - 93.01M - - - - 128.62M
Weighted Average Basic & Diluted Shares Outstanding		 - - 93.01M - - - - 128.62M

Quarterly Income Statements for Genmab A/S

No quarterly income statements for Genmab A/S are available.

Annual Cash Flow Statements for Genmab A/S

This table details how cash moves in and out of Genmab A/S's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 183 341 451 683 129 797 -887 332
Net Cash From Operating Activities		 257 0.00 199 1,057 339 1,071 1,126 1,186
Net Cash From Continuing Operating Activities		 149 0.00 595 1,384 978 1,074 1,131 1,191
Net Income / (Loss) Continuing Operations		 172 0.00 430 970 606 817 1,326 1,204
Consolidated Net Income / (Loss)		 172 - 430 970 606 817 1,326 1,204
Depreciation Expense		 - - - - - 40 49 55
Amortization Expense		 - - - - - 257 302 285
Non-Cash Adjustments To Reconcile Net Income		 - 0.00 77 143 227 -214 -523 -248
Changes in Operating Assets and Liabilities, net		 -23 - 88 271 145 174 -23 -105
Net Cash From Investing Activities		 -108 341 298 386 146 -185 -1,447 -5,643
Net Cash From Continuing Investing Activities		 -108 341 17 50 121 -185 -1,447 -5,643
Purchase of Property, Plant & Equipment		 -14 - 17 50 38 -54 -44 -55
Acquisitions		 - - - - - 0.00 -1,783 0.00
Purchase of Investments		 -553 - 0.00 0.00 16 -1,582 -1,256 -8,210
Sale and/or Maturity of Investments		 460 341 0.00 0.00 67 1,451 1,636 2,622
Net Cash From Financing Activities		 35 0.00 550 12 64 -89 -566 4,789
Net Cash From Continuing Financing Activities		 35 0.00 632 30 97 7.00 10 5,237
Repayment of Debt		 0.00 - 4.66 7.23 8.83 -14 -9.00 -286
Issuance of Debt		 - - - - - 0.00 0.00 5,500
Other Financing Activities, net		 35 - 9.77 23 21 21 19 23

Quarterly Cash Flow Statements for Genmab A/S

No quarterly cash flow statements for Genmab A/S are available.

Annual Balance Sheets for Genmab A/S

This table presents Genmab A/S's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1,298 2,275 3,475 3,748 5,232 6,414 12,873
Total Current Assets		 1,141 2,098 3,089 3,460 4,912 3,900 2,885
Cash & Equivalents		 82 534 1,193 1,363 2,204 1,380 1,715
Accounts Receivable		 204 449 405 512 733 923 1,112
Inventories, net		 - - - - 8.00 9.00 18
Plant, Property, & Equipment, net		 25 36 74 95 142 137 153
Total Noncurrent Assets		 133 142 312 193 178 2,377 9,835
Long-Term Investments		 0.00 22 178 56 20 32 37
Goodwill		 - - - - 0.00 355 355
Intangible Assets		 72 71 56 39 15 1,728 9,123
Noncurrent Deferred & Refundable Income Taxes		 59 21 29 40 31 127 171
Other Noncurrent Operating Assets		 - - 47 54 112 135 149
Total Liabilities & Shareholders' Equity		 1,298 2,275 3,475 3,748 5,232 6,414 12,873
Total Liabilities		 69 165 332 370 545 1,277 7,026
Total Current Liabilities		 68 141 206 239 368 744 1,427
Short-Term Debt		 - - - - 0.00 0.00 273
Accounts Payable		 48 126 195 225 342 489 1,069
Current Deferred & Payable Income Tax Liabilities		 20 11 - - 8.00 239 43
Other Current Liabilities		 0.00 3.91 6.90 9.44 18 16 42
Total Noncurrent Liabilities		 0.46 24 126 131 177 533 5,599
Long-Term Debt		 - - - - 0.00 0.00 5,001
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - 0.00 330 364
Other Noncurrent Operating Liabilities		 0.31 24 0.82 1.98 172 198 229
Total Equity & Noncontrolling Interests		 1,230 2,111 3,143 3,378 4,687 5,137 5,847
Total Preferred & Common Equity		 1,230 2,111 3,143 10 4,687 5,137 5,847
Preferred Stock		 1,237 1,766 1,955 1,831 1,942 1,961 1,920
Total Common Equity		 -6.90 345 1,188 1,547 2,745 3,176 3,927
Common Stock		 9.36 9.78 11 10 10 10 10
Retained Earnings		 -30 320 1,168 1,525 2,737 3,392 4,098
Other Equity Adjustments		 14 15 8.88 12 -2.00 -226 -181

Quarterly Balance Sheets for Genmab A/S

No quarterly balance sheets for Genmab A/S are available.

Annual Metrics And Ratios for Genmab A/S

This table displays calculated financial ratios and metrics derived from Genmab A/S's official financial filings.

Metric 2017 2018 2019 2020 2021 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 21.55% 73.70% 106.13% -22.32% 0.00% 30.59% 19.19%
EBITDA Growth		 0.00% -2.42% 87.19% 161.79% -55.73% 0.00% 23.76% 6.20%
EBIT Growth		 0.00% -2.42% 87.19% 161.79% -55.73% 0.00% 25.91% 9.57%
NOPAT Growth		 0.00% -14.13% 55.30% 178.48% -58.52% 0.00% 39.29% 2.56%
Net Income Growth		 0.00% 26.71% -100.00% 0.00% 0.00% 0.00% 79.56% -15.00%
EPS Growth		 0.00% 33.54% 43.41% 112.20% -36.93% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -100.00% 0.00% 430.72% -67.93% 0.00% 5.14% 5.33%
Free Cash Flow Firm Growth		 0.00% 0.00% 254.10% 491.95% -69.06% 0.00% 0.00% -682.28%
Invested Capital Growth		 0.00% 0.00% 50.14% -16.36% 17.92% 0.00% 327.54% 335.76%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 98.62% 95.42% 93.60%
EBITDA Margin		 56.83% 45.62% 49.16% 62.44% 35.58% 44.73% 42.39% 37.77%
Operating Margin		 56.83% 45.62% 49.16% 62.44% 35.58% 32.30% 31.14% 28.63%
EBIT Margin		 56.83% 45.62% 49.16% 62.44% 35.58% 32.30% 31.14% 28.63%
Profit (Net Income) Margin		 46.68% 48.66% 0.00% 0.00% 0.00% 26.40% 36.30% 25.89%
Tax Burden Percent		 103.76% 91.32% 0.00% 0.00% 0.00% 77.23% 85.44% 79.98%
Interest Burden Percent		 79.17% 116.81% 108.38% 93.52% 131.97% 105.83% 136.42% 113.05%
Effective Tax Rate		 -3.76% 8.68% 24.24% 19.41% 24.48% 22.77% 14.56% 20.02%
Return on Invested Capital (ROIC)		 0.00% 132.02% 81.97% 207.08% 86.55% 119.01% 62.85% 14.85%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 125.08% 105.00% 244.70% 98.68% 118.18% 54.42% 60.04%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -95.29% -81.97% -207.08% -86.55% -105.55% -39.78% 2.69%
Return on Equity (ROE)		 0.00% 36.74% 0.00% 0.00% 0.00% 13.46% 23.07% 17.53%
Cash Return on Invested Capital (CROIC)		 0.00% -67.98% 41.88% 224.89% 70.10% 0.00% -61.33% -110.49%
Operating Return on Assets (OROA)		 0.00% 16.31% 22.18% 36.09% 12.72% 14.76% 16.69% 11.04%
Return on Assets (ROA)		 0.00% 17.40% 0.00% 0.00% 0.00% 12.06% 19.46% 9.99%
Return on Common Equity (ROCE)		 0.00% -0.21% 0.00% 0.00% 0.00% 7.88% 13.90% 11.34%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 18.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 225 193 300 836 347 596 831 852
NOPAT Margin		 58.97% 41.66% 37.25% 50.32% 26.87% 24.95% 26.61% 22.90%
Net Nonoperating Expense Percent (NNEP)		 0.00% 6.94% -23.03% -37.62% -12.13% 0.83% 8.42% -45.19%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 12.72% 16.17% 7.66%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1.38% 4.58% 6.40%
SG&A Expenses to Revenue		 6.22% 7.07% 6.37% 6.54% 15.13% 20.00% 17.59% 16.83%
R&D to Revenue		 36.96% 47.31% 44.47% 31.03% 49.29% 46.32% 45.31% 43.17%
Operating Expenses to Revenue		 43.17% 54.38% 50.84% 37.56% 64.42% 66.32% 64.27% 64.97%
Earnings before Interest and Taxes (EBIT)		 217 212 396 1,038 459 772 972 1,065
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 217 212 396 1,038 459 1,069 1,323 1,405
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.29 3.18 2.38 1.08 0.61 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.37 3.34 2.44 1.08 1.78 0.00
Price to Revenue (P/Rev)		 0.20 0.16 0.12 2.28 2.85 1.24 0.62 0.00
Price to Earnings (P/E)		 0.42 0.33 0.00 0.00 0.00 3.85 1.71 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 238.98% 304.66% 0.00% 0.00% 0.00% 26.00% 58.37% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 4.20 2.98 11.99 9.56 5.35 1.16 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 2.65 1.63 2.65 3.21 1.12 0.80 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 5.80 3.31 4.25 9.03 2.51 1.88 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 5.80 3.31 4.25 9.03 3.47 2.56 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 6.36 4.36 5.28 11.95 4.49 3.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 6.58 4.17 12.23 2.50 2.21 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 8.54 4.86 14.75 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.01 0.02 0.00 0.00 0.90
Long-Term Debt to Equity		 0.00 0.00 0.00 0.01 0.02 0.00 0.00 0.86
Financial Leverage		 0.00 -0.76 -0.78 -0.85 -0.88 -0.89 -0.73 0.04
Leverage Ratio		 0.00 1.06 1.07 1.09 1.11 1.12 1.19 1.76
Compound Leverage Factor		 0.00 1.23 1.16 1.02 1.46 1.18 1.62 1.99
Debt to Total Capital		 0.00% 0.00% 0.00% 1.43% 1.61% 0.00% 0.00% 47.42%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.45%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.43% 1.61% 0.00% 0.00% 44.97%
Preferred Equity to Total Capital		 0.00% 100.56% 83.68% 61.32% 53.32% 41.43% 38.17% 17.26%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -0.56% 16.32% 37.26% 45.07% 58.57% 61.83% 35.31%
Debt to EBITDA		 0.00 0.00 0.00 0.04 0.12 0.00 0.00 3.75
Net Debt to EBITDA		 0.00 0.00 0.00 -1.28 -2.97 0.00 0.00 2.51
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.04 0.12 0.00 0.00 3.56
Debt to NOPAT		 0.00 0.00 0.00 0.05 0.16 0.00 0.00 6.19
Net Debt to NOPAT		 0.00 0.00 0.00 -1.59 -3.93 0.00 0.00 4.13
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.05 0.16 0.00 0.00 5.87
Altman Z-Score		 0.00 2.50 2.52 9.76 8.32 5.98 3.23 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 100.56% 89.89% 70.83% 58.05% 41.43% 39.73% 35.33%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 16.74 14.88 15.00 14.50 13.35 5.24 2.02
Quick Ratio		 0.00 4.19 6.97 7.76 7.86 7.98 3.10 1.98
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -100 153 908 281 0.00 -810 -6,340
Operating Cash Flow to CapEx		 1,785.39% 0.00% 0.00% 0.00% 0.00% 1,983.33% 2,559.09% 2,156.36%
Free Cash Flow to Firm to Interest Expense		 0.00 -58.99 145.87 3.55 2.63 0.00 -2.79 -23.57
Operating Cash Flow to Interest Expense		 4.51 0.00 189.43 4.13 3.17 4.22 3.87 4.41
Operating Cash Flow Less CapEx to Interest Expense		 4.26 0.00 205.29 4.33 3.53 4.00 3.72 4.20
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.36 0.45 0.58 0.36 0.46 0.54 0.39
Accounts Receivable Turnover		 0.00 2.28 2.47 3.89 2.81 3.26 3.77 3.66
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 4.13 16.82 17.63
Fixed Asset Turnover		 0.00 18.67 26.67 30.20 15.28 16.83 22.37 25.66
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.10 0.34 0.31
Days Sales Outstanding (DSO)		 0.00 160.12 147.78 93.79 129.68 111.94 96.83 99.84
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 88.48 21.70 20.70
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 3,782.73 1,060.54 1,194.68
Cash Conversion Cycle (CCC)		 0.00 160.12 147.78 93.79 129.68 -3,582.30 -942.01 -1,074.15
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 293 440 368 434 501 2,142 9,334
Invested Capital Turnover		 0.00 3.17 2.20 4.12 3.22 4.77 2.36 0.65
Increase / (Decrease) in Invested Capital		 0.00 293 147 -72 66 0.00 1,641 7,192
Enterprise Value (EV)		 0.00 1,229 1,311 4,411 4,146 2,679 2,490 0.00
Market Capitalization		 75 74 100 3,782 3,679 2,961 1,941 0.00
Book Value per Share		 $0.00 ($1.53) $3.70 $12.77 $16.64 $610.00 $705.78 $30.53
Tangible Book Value per Share		 $0.00 ($17.56) $2.95 $12.17 $16.22 $606.67 $242.89 ($43.16)
Total Capital		 0.00 1,230 2,111 3,188 3,433 4,687 5,137 11,121
Total Debt		 0.00 0.00 0.00 46 55 0.00 0.00 5,274
Total Long-Term Debt		 0.00 0.00 0.00 46 55 0.00 0.00 5,001
Net Debt		 0.00 -82 -556 -1,325 -1,364 -2,224 -1,412 3,522
Capital Expenditures (CapEx)		 14 0.00 -17 -50 -38 54 44 55
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 991 1,423 1,689 1,858 2,340 1,776 16
Debt-free Net Working Capital (DFNWC)		 0.00 1,072 1,957 2,883 3,222 4,544 3,156 1,731
Net Working Capital (NWC)		 0.00 1,072 1,957 2,883 3,222 4,544 3,156 1,458
Net Nonoperating Expense (NNE)		 47 -33 300 836 347 -35 -302 -111
Net Nonoperating Obligations (NNO)		 0.00 -937 -1,671 -2,775 -2,944 -4,186 -2,995 3,487
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 297 351 340
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 213.42% 176.50% 101.65% 143.96% 97.91% 56.90% 0.43%
Debt-free Net Working Capital to Revenue		 0.00% 231.04% 242.69% 173.45% 249.56% 190.13% 101.12% 46.53%
Net Working Capital to Revenue		 0.00% 231.04% 242.69% 173.45% 249.56% 190.13% 101.12% 39.19%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $34.40 $0.00 $46.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 93.01M 0.00 0.00 0.00 0.00 128.62M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $34.03 $0.00 $45.54 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 93.01M 0.00 0.00 0.00 0.00 128.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 93.01M 0.00 0.00 0.00 0.00 128.62M
Normalized Net Operating Profit after Tax (NOPAT)		 152 193 300 836 347 596 867 1,000
Normalized NOPAT Margin		 39.78% 41.66% 37.25% 50.32% 26.87% 24.95% 27.79% 26.88%
Pre Tax Income Margin		 44.99% 53.29% 53.28% 58.39% 46.96% 34.18% 42.49% 32.37%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 3.82 125.45 376.86 4.05 4.30 3.04 3.34 3.96
NOPAT to Interest Expense		 3.96 114.56 285.51 3.27 3.25 2.35 2.85 3.17
EBIT Less CapEx to Interest Expense		 3.57 125.45 392.71 4.25 4.66 2.83 3.19 3.75
NOPAT Less CapEx to Interest Expense		 3.71 114.56 301.37 3.46 3.61 2.13 2.70 2.96
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Genmab A/S

No quarterly metrics and ratios for Genmab A/S are available.


Financials Breakdown Chart

Frequently Asked Questions About Genmab A/S's Financials

When does Genmab A/S's fiscal year end?

According to the most recent income statement we have on file, Genmab A/S's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Genmab A/S's net income changed over the last 7 years?

Genmab A/S's net income appears to be on an upward trend, with a most recent value of $963 million in 2025, rising from $178.26 million in 2017. The previous period was $1.13 billion in 2024. See Genmab A/S's forecast for analyst expectations on what’s next for the company.

What is Genmab A/S's operating income?
Genmab A/S's total operating income in 2025 was $1.07 billion, based on the following breakdown:
  • Total Gross Profit: $3.48 billion
  • Total Operating Expenses: $2.42 billion
How has Genmab A/S's revenue changed over the last 7 years?

Over the last 7 years, Genmab A/S's total revenue changed from $381.86 million in 2017 to $3.72 billion in 2025, a change of 874.2%.

How much debt does Genmab A/S have?

Genmab A/S's total liabilities were at $7.03 billion at the end of 2025, a 450.2% increase from 2024, and a 10,143.7% increase since 2018.

How much cash does Genmab A/S have?

In the past 6 years, Genmab A/S's cash and equivalents has ranged from $81.78 million in 2018 to $2.20 billion in 2023, and is currently $1.72 billion as of their latest financial filing in 2025.

How has Genmab A/S's book value per share changed over the last 7 years?

Over the last 7 years, Genmab A/S's book value per share changed from 0.00 in 2017 to 30.53 in 2025, a change of 3,053.3%.


Related Companies

Financial statements for NASDAQ:GMAB last updated on 2/21/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel